These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23989028)

  • 1. Exercise preferences among men with prostate cancer receiving androgen-deprivation therapy.
    Harrington JM; Schwenke DC; Epstein DR
    Oncol Nurs Forum; 2013 Sep; 40(5):E358-67. PubMed ID: 23989028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.
    Hvid T; Winding K; Rinnov A; Dejgaard T; Thomsen C; Iversen P; Brasso K; Mikines KJ; van Hall G; Lindegaard B; Solomon TP; Pedersen BK
    Endocr Relat Cancer; 2013 Oct; 20(5):621-32. PubMed ID: 23744766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.
    Hansen PA; Dechet CB; Porucznik CA; LaStayo PC
    PM R; 2009 Nov; 1(11):1019-24. PubMed ID: 19942188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy.
    Lebret T; Coloby P; Descotes JL; Droupy S; Geraud M; Tombal B
    Urology; 2010 Dec; 76(6):1434-9. PubMed ID: 21130255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Qualitative Study Exploring the Perceptions of Sedentary Behavior in Prostate Cancer Survivors Receiving Androgen-Deprivation Therapy.
    Trinh L; Arbour-Nicitopoulos KP; Sabiston CM; Alibhai SM; Jones JM; Berry SR; Loblaw A; Faulkner GE
    Oncol Nurs Forum; 2015 Jul; 42(4):398-406. PubMed ID: 26148319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceptions of physically active men with prostate cancer on the role of physical activity in maintaining their quality of life: possible influence of androgen deprivation therapy.
    Keogh JW; Patel A; MacLeod RD; Masters J
    Psychooncology; 2013 Dec; 22(12):2869-75. PubMed ID: 23904113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
    Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
    BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
    Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
    Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Androgen deprivation therapy and morbid obesity: do they share cardiovascular risk through metabolic syndrome?].
    Cleffi S; Neto AS; Reis LO; Maia P; Fonseca F; Wroclawski ML; Neves M; Pompeo AC; Del Giglio A; Faria EF; Tobias-Machado M
    Actas Urol Esp; 2011 May; 35(5):259-65. PubMed ID: 21459486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
    Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
    Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.